BioLife Sciences Inc. Seeks to Retain an Auditing and Consulting Services Firm

Rhea-AI Summary

BioLife Sciences Inc. (OTCPK: BLFE) is taking significant steps to enhance its market presence. The company plans to engage an auditing and consulting firm with expertise in SEC filings to aid its goal of becoming fully reporting and up-listing to the OTCQB. COO Nika Jaksic emphasized the importance of this strategy, which follows the acquisition of Health Box LLC and the launch of a new life sciences division in 2022. BioLife focuses on innovative product commercialization, including sectors like orthomoleculars and nutraceuticals.

Positive

• Initiating steps to become fully reporting and potentially up-list to OTCQB.
• Acquired Health Box LLC, expanding into orthomolecular and natural health products.
• Launched a life sciences division to diversify market presence.

Negative

• None.

HENDERSON, NV, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioLife Sciences Inc. (“BioLife” or the “Company”) (OTCPK: BLFE) announced that it is seeking to retain an auditing and consulting services firm with specific expertise with SEC filings, to assist with the pursuit of becoming fully reporting with sights set on up-listing to the Over-the-Counter Quotation Bureau (“OTCQB”). 

Nika Jaksic, COO of Bio Life Sciences Inc., stated, “We are excited to announce this important next step, the assistance of experienced advisors will augment our team with the expertise necessary in achieving a successful transaction.”  

The up-listing strategy is the latest endeavor for BioLife, which began 2022 with the acquisition of the orthomolecular medicine and natural health products company Health Box LLC and the launch of a life sciences division. The company’s market focus areas include orthomoleculars, food and beverage – with a specific focus on superfoods, nutraceuticals and ethically sourced ingredients – material science and digital technology. 

About BioLife Sciences Inc.

BioLife Sciences Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption. Its core business develops, licenses and distributes antimicrobial products and disruptive technology. One of BioLife Sciences’ core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies.

Disclaimer

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the ability of the Corporation to complete a qualifying transaction. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

This is neither an offer nor a solicitation to sell securities, which may only be done once the Company’s offering on Form 1-A has been qualified by the SEC and in those certain states where the Company seeks to offer its shares.

Contact Information:
www.biolifesciences.com
ir@biolifesciences.com
US & Canada: 1 (833) 919-1037

FAQ

What is BioLife Sciences Inc. planning regarding its SEC filings?

BioLife Sciences Inc. plans to hire an auditing and consulting firm to assist with SEC filings as part of its strategy to become fully reporting.

What initiative is BioLife aiming for with its up-listing strategy?

BioLife aims to up-list to the Over-the-Counter Quotation Bureau (OTCQB) as part of its growth strategy.

What recent acquisition did BioLife Sciences Inc. make?

In early 2022, BioLife Sciences Inc. acquired Health Box LLC, focusing on orthomolecular medicine and natural health products.

What areas does BioLife Sciences Inc. focus on in its business?

BioLife focuses on orthomoleculars, superfoods, nutraceuticals, material science, and digital technology.

What does BioLife Sciences Inc. specialize in?

BioLife specializes in moving innovative products from the lab to wider market adoption, including antimicrobial products and disruptive technology.